Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 761 of 6351
-
Simple blood test could spot cancer earlier in High-Risk individuals
Diagnosis Recruiting nowThe goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes. If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer det…
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
Magic mushroom compound tested as One-Time depression fix for cancer patients
Symptom relief Recruiting nowThe goal of this randomized placebo controlled trial is to compare the antidepressant effect of a single oral dose of psilocybin 25 mg compared to 1 mg in 100 patients with cancer related major depressive disorder. The main question it aims to answer is: The primary objective of…
Phase 2 • Sponsor: Section for Affective Disorders; Northern Stockholm Psychiatry • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Weekly insulin shot could replace daily pokes for diabetes
Disease control CompletedThis study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment pa…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
AI takes the guesswork out of insulin dosing for hospital patients
Disease control CompletedOur study was a single-blind, randomised, controlled, multicentre study. The study was planned to enrol 142 patients with T2DM admitted to general wards who required subcutaneous insulin therapy. Participants were randomly divided into two groups in the ratio of 1:1, one group wi…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo aims to tackle untreated lymphoma
Disease control Recruiting nowThe purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on childhood cancer in early trial
Disease control OngoingMAGNETO is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and teenagers aged 1-16 years with relapsed or refractory neuroblastoma. The study will assess the feasibility of generating…
Phase 1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a simple supplement shield bones and kidneys from common heartburn drugs?
Prevention CancelledProton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragili…
Phase 3 • Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Can exercise boost reading recovery in stroke survivors?
Disease control Recruiting nowThe goal of the proposed project is to test the effectiveness of a novel hybrid approach to treatment of reading disorders after stroke, in which exercise training will be used in combination with a targeted reading treatment. This approach is expected to increase cerebral circul…
Sponsor: Kessler Foundation • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New targeted therapy aims to keep bladder cancer at bay
Disease control Recruiting nowThe main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New CAR t therapy aims to tackle tough leukemia
Disease control Recruiting nowThe purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this …
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immune cells from your tumor could fight cancer again
Disease control Recruiting nowThis study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307 injection ) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determin…
Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Gene therapy breakthrough? early trial for blood disorder shows promise
Disease control CompletedThe goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-thalassemia major anemia.
Phase 1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Promising new combo aims to improve remission in Tough-to-Treat leukemia
Disease control Recruiting nowThe purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML).
Phase 2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy targets hard-to-treat lung cancer
Disease control Recruiting nowThe purpose of this study was to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) combined with sugemalimab, olaparib, chemotherapy in the first-line treatment of SLFN-11 positive extensive stage small cell lung cancer.
Phase 1/2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Promising combo therapy for brain lining cancer shows hope in new trial
Disease control Recruiting nowIntrathecal chemotherapy is one of the mainstay treatment options for leptomeningeal metastases. Pemetrexed is one of the first-line chemotherapeutic agents for non-squamous non-small cell lung cancer (NSCLC). Since 2017, intrathecal pemetrexed has shown good efficacy for patient…
Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug shows promise for Tough-to-Treat stomach cancer
Disease control CompletedThe study is a open-label, single-arm, multicenter, phase Ib/II trial assessing the efficacy of sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma
Phase 1/2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can this drug fully heal the gut in Crohn's?
Disease control OngoingThe purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
Phase 3 • Sponsor: Janssen-Cilag Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Inhaled virus takes on lung tumors in new trial
Disease control Recruiting nowThe Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is admi…
Phase 1/2 • Sponsor: Krystal Biotech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cocktail targets HER2-Positive bile duct cancer in small trial
Disease control OngoingThis is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity triplet regimen consisting of a combination of chemotherapy (gemcitabine/cisplatin) + trastuzumab + pembrolizumab as first-line treatment for cholangiocarcinoma and gallb…
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Could a lung drug save kidneys in liver patients?
Disease control OngoingPatients with advanced cirrhosis of the liver develop kidney problems occasionally. This condition is called Hepatorenal Syndrome, requires hospitalization and frequently results in death. The goal of this clinical trial is to test whether the administration of low doses of ambr…
Phase 2 • Sponsor: Noorik Biopharmaceuticals AG • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC